You're describing a very specific and complex molecule. Let's break it down:
**1, 3-di-(n-carboxybenzoyl-leucyl-leucyl)amino acetone**
* **1, 3-di-**: Indicates two identical units are attached at the 1st and 3rd positions of the molecule.
* **(n-carboxybenzoyl-leucyl-leucyl)amino**: This is a complex amino acid sequence. Here's the breakdown:
* **n-carboxybenzoyl**: This is a benzoic acid derivative with a carboxyl group attached to a nitrogen atom.
* **leucyl**: This is the amino acid leucine. The leucyl portion indicates the amino group is linked to another molecule.
* **amino**: This indicates the presence of an amine group (-NH2).
* **acetone**: This is the organic molecule propanone, a common solvent.
**Putting it all together:** The molecule consists of an acetone backbone with two identical chains attached. Each chain is composed of a benzoyl group, two leucine amino acids, and a carboxyl group.
**Importance for Research:**
You've described a molecule that likely doesn't have a well-established role in standard biological research. It's very specific and likely designed for a particular application. Here's why it might be relevant:
* **Drug Discovery**: It could be a synthetic compound designed as a potential drug or drug lead. The presence of amino acids suggests it might interact with biological targets.
* **Material Science**: It could be a building block for new materials with specific properties, potentially related to biocompatibility or controlled drug release.
* **Analytical Chemistry**: It could be a standard or reagent used in specialized analytical techniques.
**To understand the specific importance, you need additional information:**
* **Who synthesized it?** Researchers often develop and publish on novel compounds.
* **What is the context?** Where did you encounter this molecule? In a research paper, a patent, or a chemical catalog?
Let me know if you can provide more context, and I might be able to give you a more specific answer.
1, 3-di-(N-carboxybenzoyl-leucyl-leucyl)amino acetone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44449123 |
| CHEMBL ID | 255473 |
| SCHEMBL ID | 4669748 |
| MeSH ID | M0372251 |
| Synonym |
|---|
| (z-ll)2 ketone |
| 1, 3-di-(n-carboxybenzoyl-leucyl-leucyl)amino acetone |
| CHEMBL255473 , |
| SCHEMBL4669748 |
| 2,2'-(2-oxo-1,3-propanediyl)bis[n-[(phenylmethoxy)carbonyl]-l-leucyl-l-leucinamide |
| 313664-40-3 |
| AKOS025293514 |
| (z-ll)2 ketone, >=98% (hplc) |
| mfcd04974180 |
| (z-ll)2ketone |
| bdbm50263008 |
| benzyl n-[(2s)-4-methyl-1-[[(2s)-4-methyl-1-[[3-[[(2s)-4-methyl-2-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]-2-oxopropyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate |
| PD069426 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Presenilin-1 | Homo sapiens (human) | IC50 (µMol) | 1.0343 | 0.0001 | 0.2378 | 5.6800 | AID329706; AID329707 |
| Presenilin-2 | Homo sapiens (human) | IC50 (µMol) | 1.0343 | 0.0001 | 0.2435 | 5.6800 | AID329706; AID329707 |
| Signal peptide peptidase-like 2A | Homo sapiens (human) | IC50 (µMol) | 0.0060 | 0.0060 | 0.0080 | 0.0100 | AID1479248 |
| Gamma-secretase subunit APH-1B | Homo sapiens (human) | IC50 (µMol) | 1.0343 | 0.0001 | 0.2435 | 5.6800 | AID329706; AID329707 |
| Nicastrin | Homo sapiens (human) | IC50 (µMol) | 1.0343 | 0.0001 | 0.2435 | 5.6800 | AID329706; AID329707 |
| Gamma-secretase subunit APH-1A | Homo sapiens (human) | IC50 (µMol) | 1.0343 | 0.0001 | 0.2435 | 5.6800 | AID329706; AID329707 |
| Gamma-secretase subunit PEN-2 | Homo sapiens (human) | IC50 (µMol) | 1.0343 | 0.0001 | 0.2442 | 5.6800 | AID329706; AID329707 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID329706 | Displacement of [3H]L685458 from gamma-secretase in human THP1 cells | 2007 | The Journal of biological chemistry, Dec-21, Volume: 282, Issue:51 | Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. |
| AID329703 | Inhibition of SPP expressed in HEK293 cells in presence of Prl-PP peptide after 30 mins | 2007 | The Journal of biological chemistry, Dec-21, Volume: 282, Issue:51 | Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. |
| AID1479249 | Selectivity ratio of IC50 for human gamma-secretase expressed in HEK293 cells to IC50 for human SPPL2a expressed in HEK293 cells | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. |
| AID329705 | Displacement of [3H]L685458 from human SPP expressed in HEK293 cells | 2007 | The Journal of biological chemistry, Dec-21, Volume: 282, Issue:51 | Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. |
| AID1479247 | Inhibition of human gamma-secretase expressed in HEK293 cells using Notch1-VP16-Gal4 as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. |
| AID329707 | Displacement of [3H]IN973 from gamma-secretase in human THP1 cells | 2007 | The Journal of biological chemistry, Dec-21, Volume: 282, Issue:51 | Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. |
| AID1479248 | Inhibition of human SPPL2a expressed in HEK293 cells using GAL4-VP16 fusedTNFalpha (1 to 76)-NTF as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||